CoChat

The Impact of Flash Glucose Monitoring on Glycaemic Control as Measured by HbA1c: A Meta-analysis of Clinical Trials and Real-World Observational Studies

Open access
Evans, Mark, Welsh, Zoë, Ells, Sara, Seibold, Alexander · 2020 · Diabetes Therapy

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Abstract

Glycated haemoglobin A1c (HbA1c) is the established standard measurement for assessment of glycaemic control in people with diabetes. Here we report on a meta-analysis of real-world observational studies on the impact of flash continuous glucose monitoring on glycaemic control as measured by HbA1c. A total of 271 studies were identified in our search, of which 29 contained data reporting changes in HbA1c over periods from 1 to 24 months that could be used in a statistical analysis. Our meta-analysis focuses on observed change in HbA1c at either 2, 3 or 4 months, in adult or paediatric subjects, as well as a longitudinal analysis up to 12 months in adult subjects. These data were drawn from 25 of the studies identified in our initial search. These reported HbA1c data up to 12 months in a total of 1723 participants with type 1 diabetes (T1D) or type 2 diabetes (T2D) using the FreeStyle Libre ® flash glucose monitoring system. Overall mean change in laboratory HbA1c across study subjects at 2–4 months was − 0.55% (95% CI − 0.70, − 0.39). Amongst the 1023 adults, mean change in HbA1c was − 0.56% (95% CI − 0.76, − 0.36); for the 447 children and adolescents, mean change in HbA1c was − 0.54% (95% CI − 0.84, − 0.23). Based on regression analysis, the degree of change in HbA1c correlated with the initial HbA1c of the study population. A longitudinal analysis in adult subjects ( n = 1276) shows that HbA1c fell within the first 2 months and changes were sustained up to 12 months. No significant differences were detected between T1D and T2D. The meta-analysis reported here confirms that starting the FreeStyle Libre system as part of diabetes care results in a significant and sustained reduction in HbA1c for adults and children with T1D and for adults with T2D. Abbott Diabetes Care.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s13300-019-00720-0

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Search strategy and study selection
Fig. 1 Search strategy and study selectionCC BY-NC · PubMed Central
Fig. 2 Limitations of this meta-analysis
Fig. 2 Limitations of this meta-analysisCC BY-NC · PubMed Central
Fig. 3 a Forest plot for change in HbA1c at 2–4 months using random effects model. The areas of the squares are proportional to the weight of the study. A total of 21 studies with 2–4-month outcomes data were included in the analysis and are shown in order of mean initial HbA1c, with the highest at the bottom. Overall mean change in HbA1c was − 0.55, 95% CI − 0.70, − 0.39. Heterogeneity: τ2= 0.09, Q = 337.7 (p < 0.0001), I2= 94.1%. b Forest plot for change in HbA1c at 2–4 months in adult subjects using random effects model. The areas of the squares are proportional to the weight of the study. Twelve studies with 2–4-month outcomes data were included in the analysis. For adults, overall mean change in HbA1c was − 0.56, 95% CI − 0.76, − 0.36. Heterogeneity: τ2= 0.08, Q = 164.0 (p < 0.0001), I2= 93.3%. c Forest plot for change in HbA1c at 2–4 months in children and adolescent subjects using random effects model. The areas of the squares are proportional to the weight of the study. Nine studies with 2–4-month outcomes data were included in the analysis. For children and adolescents, overall mean change in HbA1c was − 0.54, 95% CI − 0.84, − 0.23. Heterogeneity: τ2= 0.11, Q = 130.3 (p < 0.0001), I2= 93.9%
Fig. 3 a Forest plot for change in HbA1c at 2–4 months using random effects model. The areas of the squares are proportional to the weight of the study. A total of 21 studies with 2–4-month outcomes data were included in the analysis and are shown in order of mean initial HbA1c, with the highest at the bottom. Overall mean change in HbA1c was − 0.55, 95% CI − 0.70, − 0.39. Heterogeneity: τ2= 0.09, Q = 337.7 (p < 0.0001), I2= 94.1%. b Forest plot for change in HbA1c at 2–4 months in adult subjects using random effects model. The areas of the squares are proportional to the weight of the study. Twelve studies with 2–4-month outcomes data were included in the analysis. For adults, overall mean change in HbA1c was − 0.56, 95% CI − 0.76, − 0.36. Heterogeneity: τ2= 0.08, Q = 164.0 (p < 0.0001), I2= 93.3%. c Forest plot for change in HbA1c at 2–4 months in children and adolescent subjects using random effects model. The areas of the squares are proportional to the weight of the study. Nine studies with 2–4-month outcomes data were included in the analysis. For children and adolescents, overall mean change in HbA1c was − 0.54, 95% CI − 0.84, − 0.23. Heterogeneity: τ2= 0.11, Q = 130.3 (p < 0.0001), I2= 93.9%CC BY-NC · PubMed Central
Fig. 4 Bubble chart of mean change in HbA1c at 2–4 months versus mean initial HbA1c. The area of each bubble represents the weight of the study. The regression line from meta-regression random effects model is displayed for 21 studies with 2–4-month outcomes data. Slope = − 0.31 (SE = 0.056, 95% CI − 0.43 to − 0.19). Mean initial HbA1c explains a considerable proportion of the heterogeneity between trials in change in HbA1c. Homogeneity: τ2= 0.02, Q = 56.2 (p < 0.0001), I2= 66.2%. On average, for each percentage increase in mean initial HbA1c, the mean change in final HbA1c drops by 0.31%, 95% CI − 0.43 to − 0.19. For example, this analysis indicates that if the mean initial HbA1c is 8.5%, the expected mean reduction in HbA1c is 0.6%, a final HbA1c of 7.9%
Fig. 4 Bubble chart of mean change in HbA1c at 2–4 months versus mean initial HbA1c. The area of each bubble represents the weight of the study. The regression line from meta-regression random effects model is displayed for 21 studies with 2–4-month outcomes data. Slope = − 0.31 (SE = 0.056, 95% CI − 0.43 to − 0.19). Mean initial HbA1c explains a considerable proportion of the heterogeneity between trials in change in HbA1c. Homogeneity: τ2= 0.02, Q = 56.2 (p < 0.0001), I2= 66.2%. On average, for each percentage increase in mean initial HbA1c, the mean change in final HbA1c drops by 0.31%, 95% CI − 0.43 to − 0.19. For example, this analysis indicates that if the mean initial HbA1c is 8.5%, the expected mean reduction in HbA1c is 0.6%, a final HbA1c of 7.9%CC BY-NC · PubMed Central
Fig. 5 Mean change in HbA1c with flash glucose monitoring is sustained over 12 months in adult subjects. HbA1c is significantly reduced from 2 months onwards in adult subjects. No significant differences were detected between type 1 and type 2 diabetes (95% CI − 0.51 to 0.17, p = 0.2883). HbA1c level reduces each month to approximately 2 months, after which the reduction is maintained to 12 months
Fig. 5 Mean change in HbA1c with flash glucose monitoring is sustained over 12 months in adult subjects. HbA1c is significantly reduced from 2 months onwards in adult subjects. No significant differences were detected between type 1 and type 2 diabetes (95% CI − 0.51 to 0.17, p = 0.2883). HbA1c level reduces each month to approximately 2 months, after which the reduction is maintained to 12 monthsCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Research works printed but not linked: 12

  1. Gibb FW, Stimson RH, Zammitt NN, et al. Flash glucose monitoring is associated with improved glycaemic control and quality of life in people with type 1 diabetes: a large ‘real-world’ assessment. Diabetologia. 2018;16(S1):S391.
  2. Xatzipsalti M, Mentesidou L, Kourti A, et al. Flash glucose monitoring system improves glycemic control. Pediatr Diabetes. 2017;18(Suppl. 25):78.
  3. Helm N, De ML, Forsman S, et al. Flash glucose monitoring improves perception and frequency of glucose monitoring leading to improved glucose control. Pediatr Diabetes. 2016;17:115.
  4. Wijnands A, Gys I, Bevilacqua E, et al. The FreeStyle flash glucose monitoring system has limited effect on the metabolic control of children and adolescents with type 1 diabetes mellitus. Pediatr Diabetes. 2017;18(Suppl. 25):38.
  5. Walton-Betancourth S, Amin R. A clinic-based study of the impact of flash glucose sensing technology on glycaemic control and self-monitoring of blood glucose in children and young people with type 1 diabetes. Pediatr Diabetes. 2017;18(Suppl. 25):47.
  6. Bacon S, O’Dwyer B, Chambers C, et al. The performance and technical usability of a flash glucometer monitoring system. Irish J Med Sci. 2017;186(9):S357.
  7. Karlsson E. HbA1c after one year of use of flash glucose monitoring in patients with type 1 diabetes. Thesis, University of Orebero, Sweden.
  8. Abdalaziz A, Lan K, Bilous M, et al. Flash glucose monitoring (FGM) in people with type 1 diabetes: single centre-real-world experience. Diabetes Med. 2018;35(S1):168.
  9. Löndahl M, Filipsson K, Lindholm E, et al. Effect of flash glucose monitoring on metabolic control and self-esteem treatment satisfaction in people with T1DM. Diabetes Technol Ther. 2017;19(S1):A-81.
  10. Holcombe A, Karunakaran V, Streeting J, et al. Trial of FreeStyle Libre in a local service: impact on diabetes outcomes. Diabetes Med. 2017;34(S1):160.
  11. Tirelli E, Frontino G, Favalli V, et al. Flash glucose monitoring in noncompliant children and adolescents with type 1 diabetes. Diabetes Technol Ther. 2017;19(S1):A-83.
  12. Hey C, Alkharaiji M, Anyanwagu U, et al. Impact of FreeStyle Libre on glycaemic control, frequency of glucose monitoring and treatment satisfaction. Diabetes Med. 2018;35(Supplement 1):195.

Cited by

See all 185

Metadata

Authors
Evans, M., Welsh, Z., Ells, S., & Seibold, A.
Affiliations
  • University of Cambridge (GB)
  • Abbott (United Kingdom) (GB)
  • Abbott (Germany) (DE)
Corresponding author
Evans, Mark
Venue
Diabetes Therapy
Published
2019-10-31
Volume
11
Issue
1
Pages
83-95
ISSN
  • 1869-6953 (ISSN-L)
  • 1869-6961
OpenAlex
W2985334076
Cited by
185
References
36
Citations by year
2026: 15 · 2025: 20 · 2024: 23 · 2023: 26 · 2022: 40 · 2021: 33 · 2020: 28
FWCI
3.87
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetes Therapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Apollo (University of Cambridge) (submittedVersion, cc-by-nc)
  • Apollo (University of Cambridge) (submittedVersion)
  • Apollo
Funders
Abbott Diabetes Care
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
flash glucose monitoring, continuous glucose monitoring, HbA1c, glycemic control, type 1 diabetes, type 2 diabetes, FreeStyle Libre, pediatric diabetes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Impact of Flash Glucose Monitoring on Glycaemic Control as Measured by HbA1c: A Meta-analysis of Clinical Trials and Real-World Observational Studies. https://app.cochat.ai/papers/10.1007/s13300-019-00720-0
The paper
Evans, M., Welsh, Z., Ells, S., & Seibold, A. (2020). The Impact of Flash Glucose Monitoring on Glycaemic Control as Measured by HbA1c: A Meta-analysis of Clinical Trials and Real-World Observational Studies. Diabetes Therapy. https://doi.org/10.1007/s13300-019-00720-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.